Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 May;89(5):573-575.
doi: 10.1007/s00280-022-04422-6. Epub 2022 Apr 1.

Lurbinectedin-induced thrombocytopenia: the role of body surface area

Apostolos Papachristos  1 , Mark J Ratain  2   3
Affiliations
Editorial

Lurbinectedin-induced thrombocytopenia: the role of body surface area

Apostolos Papachristos et al. Cancer Chemother Pharmacol. 2022 May.

Abstract

Lurbinectedin is an alkylating agent approved for the second-line treatment of small cell lung cancer. Although initial studies showed no association between body surface area (BSA) and drug clearance, the recommended dose is 3.2 mg/m2 every 3 weeks. This recommendation was based on an exposure-response study, which demonstrated that patients with lower BSA had a higher incidence of thrombocytopenia. Herein we present the factors associated with BSA and thrombopoiesis, which may have contributed to the observed relationship.

Keywords: Body surface area; Exposure–response; Flat dose; Lurbinectedin; Thrombocytopenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Singh S, Jaigirdar AA, Mulkey F, Cheng J, Hamed SS, Li Y, Liu J, Zhao H, Goheer A, Helms WS, Wang X, Agarwal R, Pragani R, Korsah K, Tang S, Leighton J, Rahman A, Beaver JA, Pazdur R, Theoret MR, Singh H. FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer. Clin Cancer Res. 2021;27(9):2378–2382. doi: 10.1158/1078-0432.Ccr-20-3901. - DOI - PMC - PubMed
    1. Belgiovine C, Bello E, Liguori M, Craparotta I, Mannarino L, Paracchini L, Beltrame L, Marchini S, Galmarini CM, Mantovani A, Frapolli R, Allavena P, D'Incalci M. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer. 2017;117(5):628–638. doi: 10.1038/bjc.2017.205. - DOI - PMC - PubMed
    1. Leal JF, Martínez-Díez M, García-Hernández V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillén-Navarro MJ, Avilés P, Cuevas C, García-Fernández LF, Galmarini CM. PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol. 2010;161(5):1099–1110. doi: 10.1111/j.1476-5381.2010.00945.x. - DOI - PMC - PubMed
    1. Santamaría Nuñez G, Robles CM, Giraudon C, Martínez-Leal JF, Compe E, Coin F, Aviles P, Galmarini CM, Egly JM. Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells. Mol Cancer Ther. 2016;15(10):2399–2412. doi: 10.1158/1535-7163.Mct-16-0172. - DOI - PubMed
    1. Xie W, Forveille S, Iribarren K, Sauvat A, Senovilla L, Wang Y, Humeau J, Perez-Lanzon M, Zhou H, Martínez-Leal JF, Kroemer G, Kepp O. Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity. Oncoimmunology. 2019;8(11):e1656502. doi: 10.1080/2162402X.2019.1656502. - DOI - PMC - PubMed

Publication types

LinkOut - more resources